Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Shakthi Bhaskar"'
Autor:
Madiha Iqbal, Arushi Khurana, Julio Chavez, Allison C. Rosenthal, Zhuo Li, Emily Craver, Saha Aditi, Narendranath Epperla, Kaitlin Annunzio, Farrukh T. Awan, Iris Isufi, Bhagirathbhai Dholaria, Shakthi Bhaskar, Joseph Maakaron, Nuttavut Sumransub, Andrew Fijalka, Jose Sandoval-Sus, Stanislav Ivanov, Yi Lin, Mohamed A. Kharfan-Dabaja
Publikováno v:
Blood. 140:10396-10398
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8b26f74e37cf6900bb95044621b361db
https://doi.org/10.1182/blood-2022-169689
https://doi.org/10.1182/blood-2022-169689
Autor:
Shakthi Bhaskar, Vivek Patel, David L. Porter, Stephen J. Schuster, Loretta J. Nastoupil, Miguel-Angel Perales, Ana Alarcon Tomas, Michael R. Bishop, Joseph P. McGuirk, Richard T. Maziarz, Andy Chen, Veronika Bachanova, Peter A. Riedell, Olalekan O. Oluwole
Publikováno v:
Blood. 140:10971-10973
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::271d861609033e007efe3409d8b2b7a6
https://doi.org/10.1182/blood-2022-155886
https://doi.org/10.1182/blood-2022-155886
Autor:
Vivek Patel, Shakthi Bhaskar, Stephen J. Schuster, Loretta J. Nastoupil, Miguel-Angel Perales, Roni Shouval, Joseph P. McGuirk, Richard T. Maziarz, Andy Chen, Veronika Bachanova, David L. Porter, Michael R. Bishop, Peter A. Riedell, Olalekan O. Oluwole
Publikováno v:
Blood. 140:366-368
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0a2dd1cd08618389c57fa0392a00ec19
https://doi.org/10.1182/blood-2022-165556
https://doi.org/10.1182/blood-2022-165556
Autor:
Bipin N. Savani, Shakthi Bhaskar, Bhagirathbhai Dholaria, Salyka Sengsayadeth, Olalekan O. Oluwole
Publikováno v:
EJHaem. 3(Suppl 1)
Chimeric antigen receptor (CAR) T-cell therapy has been approved for use in several relapsed/refractory hematologic malignancies and has significantly improved outcomes for these diseases. A number of different CAR T products are now being used in cl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::39ecf99ad67d47afed5f3d3f1d9a0fc2
https://pubmed.ncbi.nlm.nih.gov/35844303
https://pubmed.ncbi.nlm.nih.gov/35844303
Autor:
Vivek Patel, Shakthi Bhaskar, Christopher G Cann, Jennifer Green, Sanjay Mohan, Katherine Jean Walsh, Megan Dupuis
Publikováno v:
Journal of Clinical Oncology. 40:11027-11027
11027 Background: Journal club (JC) is an essential tool in hematology/oncology fellowship to develop critical appraisal skills. The traditional JC format of reviewing an article followed by group discussion may not provide optimal education in appra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e6d204c172dbda20db3c8994a789186c
https://doi.org/10.1200/jco.2022.40.16_suppl.11027
https://doi.org/10.1200/jco.2022.40.16_suppl.11027
Publikováno v:
BMJ Case Rep
Anaplastic lymphoma kinase-positive large B-cell lymphoma (ALK+ LBCL) is known to be a rare and aggressive form of lymphoma that relapses quickly after both conventional chemotherapy and more targeted therapy. Lenalidomide is an immunomodulator that
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::808ed2bc62224ab683d071a29d9367e8
https://pubmed.ncbi.nlm.nih.gov/32843459
https://pubmed.ncbi.nlm.nih.gov/32843459
Autor:
Shakthi Bhaskar, Nivetha Ganesan, Michael A. Spinner, Promie Faruque, Neha Mehta-Shah, Ranjana H. Advani, Carrie van der Weyden, Neval Ozkaya, Judith Trotman, Alison J. Moskowitz, Venkatraman E. Seshan, Ahmet Dogan, H. Miles Prince, Paola Ghione, Jia Ruan, Giorgio Inghirami, Steven M. Horwitz, James Yeung, Matthew A. Lunning, Natasha Galasso
Publikováno v:
Blood Adv
Histone deacetylase inhibitors (HDACi) are active agents for peripheral T-cell lymphoma (PTCL). Anecdotally angioimmunoblastic T-cell lymphoma (AITL) appears to respond better than PTCL–not otherwise specified (NOS) to HDACi. The new World Health O
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d510491c39f3d3f249660cafd625928
https://pubmed.ncbi.nlm.nih.gov/33002132
https://pubmed.ncbi.nlm.nih.gov/33002132
Autor:
Rachel Kositsky, Andrew Ip, Shakthi Bhaskar, Rakhee Vaidya, Andre Goy, Ahmed Galal, Tushar Dave, Nirav N. Shah, Charalambos Andreadis, Deborah M. Stephens, Eric D. Hsi, Kavya Kannan, Swetha Kambhampati, Boyu Hu, Kenneth Ofori, Matthew McKinney, Sandeep S. Dave, Chrissie Rozzi, Caroline J Roth, Robert Ferdman, Joanna C. Zurko, Nilanjan Ghosh, John M. Pagel, Brian T. Hill, Ellen K. Kendall, Ashley M. Cunningham, Elizabeth Thacker, Neil Bailey, Jadee L. Neff, Matthew Chiaramonte, George Chen, Alexandra E. Kovach, Robert S. Ohgami, Govind Bhagat, Ran Reshef, Olalekan O. Oluwole, Tarsheen K. Sethi, Agrima Mian, Cassandra Love, Sarah L. Ondrejka, Lanie Happ, Clay Parker, Francisco J. Hernandez-Ilizaliturri, Monalisa Ghosh, Krish Patel, Emily F. Mason, Christopher Pallas
Publikováno v:
Blood. 138:165-165
INTRODUCTION Diffuse large B-cell lymphoma (DLBCL) represents several distinct clinical pathologic entities recently identified by molecular profiling. Treatment with anti-CD19 chimeric antigen receptor (CAR) T-cell therapies is now standard for many
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::263fdfa7dcca8e6ac17f2cfe598aab81
https://doi.org/10.1182/blood-2021-145764
https://doi.org/10.1182/blood-2021-145764
Publikováno v:
Blood. 136:42-42
Background: High-dose methotrexate (HD-MTX) with leucovorin rescue is frequently used in the treatment of various lymphomas, breast cancer, and sarcomas and remains an important therapy for lymphoma with CNS involvement. Despite its efficacy, HD-MTX
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::036fafdbf8c448f958bc63f22036e906
https://doi.org/10.1182/blood-2020-137536
https://doi.org/10.1182/blood-2020-137536
Autor:
Don M. Benson, Shakthi Bhaskar
Publikováno v:
International Journal of Hematologic Oncology. 4:23-31
SUMMARY Multiple myeloma (MM) is a hematologic malignancy associated with heterogeneous treatment and survival outcomes due in part to the ability of MM to evade and suppress the immune system. Research has focused on finding ways to modulate and enh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e4ac56607bb40c0cdeee9680443a22ba
https://doi.org/10.2217/ijh.14.43
https://doi.org/10.2217/ijh.14.43